---
title: "Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Prevalence"
description: "Formulary evidence on Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Prevalence. Topics: U.S. women living with breast cancer, all stages; U.S. women living with metastatic breast cancer, 2013 and 2017; U.S. women living with metastatic breast cancer: duration since metastatic diagnosis; U.S. individuals living with metastatic female breast cancer, 2018 estimate and 2025 projection; 2 further topics. 6 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description/prevalence"
published: "2026-11-15T20:23:25-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Prevalence

<a id="heading-2.2.1.2.2"></a>

## 2.2.1.2.2 Prevalence of Previously treated ER-positive HER2-negative advanced or metastatic breast cancer

<a id="topic-2.2.1.2.2-1"></a>

### U.S. women living with breast cancer, all stages

> “In 2023, there were an estimated 4,238,585 women living with female breast cancer in the United States.”

Source: [SEER Cancer Stat Facts Female Breast Cancer (2026)](https://seer.cancer.gov/statfacts/html/breast.html)

<a id="topic-2.2.1.2.2-2"></a>

### U.S. women living with metastatic breast cancer, 2013 and 2017

> “In 2013, the last year with observed data, we estimate a prevalence of MBC of 138,622 of which 38,897 (28%) are survivors who were initially diagnosed with de novo stage IV disease and 99,725 (72%) survivors initially diagnosed with stage I–III BC who later progressed to MBC”
> “We project that by 1/1/2017 there will be 154,794 women living with MBC in the United States.”

Source: [Mariotto et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5833304/)

<a id="topic-2.2.1.2.2-3"></a>

### U.S. women living with metastatic breast cancer: duration since metastatic diagnosis

> “Although the largest majority of prevalent cases are women who have been living with metastatic disease for 2 years or less (40%), one third (34%) have lived for 5 years or more with MBC”

Source: [Mariotto et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5833304/)

<a id="topic-2.2.1.2.2-4"></a>

### U.S. individuals living with metastatic female breast cancer, 2018 estimate and 2025 projection

| Measure | Breast (female) |
| --- | --- |
| Number living with metastatic disease on January 1, 2018, de novo (observed) | “54 117” |
| Number living with metastatic disease on January 1, 2018, de novo and recurrence (estimated) | “140 230” |
| Projected number living with metastatic disease (de novo and recurrence) on January 1, 2025 | “169 347” |

Source: [Gallicchio et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9949565/)

> “Almost 30% of individuals diagnosed with metastatic melanoma and one-fifth of individuals diagnosed with metastatic colorectal or metastatic breast cancer are estimated to have been living with metastatic disease for 10 or more years”
> “The number of individuals living with metastatic cancer is projected to increase from 2019 to 2025 for breast, bladder, colorectal, and prostate cancer”

Source: [Gallicchio et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9949565/)

<a id="topic-2.2.1.2.2-5"></a>

### U.S. share of women living with metastatic disease first diagnosed at stage I to III

> “Notably, a recent study estimated that 61% of women living with metastatic breast cancer were originally diagnosed with stage I–III disease.”

Source: [Giaquinto et al. (2024)](https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21863)

<a id="topic-2.2.1.2.2-6"></a>

### U.S. prevalence of previously treated ER-positive HER2-negative advanced disease

No evidence found.

<a id="topic-2.2.1.2.2-7"></a>

### Worldwide 5-year prevalence of breast cancer by continent, GLOBOCAN 2024

| Continent | 5-year prevalent cases | Percent |
| --- | --- | --- |
| Asia | “3 291 849” | “40.3%” |
| Europe | “2 208 013” | “27.1%” |
| Northern America | “1 373 135” | “16.8%” |
| Latin America and the Caribbean | “670 478” | “8.2%” |
| Africa | “491 878” | “6.0%” |
| Oceania | “126 982” | “1.6%” |

Source: [International Agency for Research on Cancer GLOBOCAN breast fact sheet (2026)](https://gco.iarc.who.int/media/globocan/factsheets/cancers/20-breast-fact-sheet.pdf)

## Related pages
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Terms and abbreviations](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations.md)
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product information and disease description](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical evidence](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic information and modeling report](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: References](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references.md)
